Tango Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 21.91 USD (Oct 30, 2026, 3:18 PM EDT) · Market cap 3.69B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ...